CA1112172A - Antidote consisting of particles of activated carbon - Google Patents
Antidote consisting of particles of activated carbonInfo
- Publication number
- CA1112172A CA1112172A CA318,549A CA318549A CA1112172A CA 1112172 A CA1112172 A CA 1112172A CA 318549 A CA318549 A CA 318549A CA 1112172 A CA1112172 A CA 1112172A
- Authority
- CA
- Canada
- Prior art keywords
- activated carbon
- antidote
- particles
- spherical particles
- diameter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 153
- 239000002245 particle Substances 0.000 title claims abstract description 23
- 239000000729 antidote Substances 0.000 title claims abstract description 14
- 239000012798 spherical particle Substances 0.000 claims abstract description 42
- 239000011148 porous material Substances 0.000 claims abstract description 12
- 231100000765 toxin Toxicity 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 abstract description 17
- 229910052799 carbon Inorganic materials 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 12
- 230000002605 anti-dotal effect Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 3
- 229960000511 lactulose Drugs 0.000 description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000003763 carbonization Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 229960001576 octopamine Drugs 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000013094 purity test Methods 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002146 exchange transfusion Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- ASHGTUMKRVIOLH-UHFFFAOYSA-L potassium;sodium;hydrogen phosphate Chemical compound [Na+].[K+].OP([O-])([O-])=O ASHGTUMKRVIOLH-UHFFFAOYSA-L 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- -1 sawdust Chemical compound 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000004227 thermal cracking Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15654677A JPS5489010A (en) | 1977-12-27 | 1977-12-27 | Spherical activated charcoal antidote |
| JP156546/1977 | 1977-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1112172A true CA1112172A (en) | 1981-11-10 |
Family
ID=15630152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA318,549A Expired CA1112172A (en) | 1977-12-27 | 1978-12-22 | Antidote consisting of particles of activated carbon |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS5489010A (enExample) |
| CA (1) | CA1112172A (enExample) |
| DE (1) | DE2855825C2 (enExample) |
| ES (1) | ES476321A1 (enExample) |
| FR (1) | FR2413092A1 (enExample) |
| GB (1) | GB2012257B (enExample) |
| NL (1) | NL7812550A (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS565313A (en) * | 1979-06-26 | 1981-01-20 | Kureha Chem Ind Co Ltd | Detoxificating spherical active carbon and preparing the same |
| US4761284A (en) * | 1977-12-27 | 1988-08-02 | Kureha Kagaku Kogy Kabushiki Kaisha | Antidote including activated carbon particles |
| JPS5673542A (en) * | 1979-11-22 | 1981-06-18 | Kureha Chem Ind Co Ltd | Adsorbent |
| JPS5731864A (en) * | 1980-08-04 | 1982-02-20 | Teijin Ltd | Oral activated carbon microcapsule |
| DE3819000A1 (de) * | 1988-06-03 | 1989-12-14 | Hasso Von Bluecher | Beutel in der art eines teebeutels zur beseitigung von schadstoffen |
| IT1273678B (it) * | 1993-08-12 | 1997-07-09 | Bluecher Hasso Von | Processo per la produzione di carbone attivo |
| NL1000078C2 (nl) * | 1994-04-19 | 1996-04-22 | Bluecher Hasso Von | Geurfilter voor stofzuigers. |
| SE515506C2 (sv) * | 1994-06-17 | 2001-08-20 | Mhb Filtration Gmbh & Co Kg | Luktfilter för ventilationsutloppshuvar |
| SE509743C2 (sv) * | 1994-06-17 | 1999-03-01 | Bluecher Hasso Von | Adsorptionsfilterskikt |
| FR2745981B1 (fr) * | 1996-03-15 | 1998-06-05 | Agent adsorbant diminuant ou eliminant les effets secondaires lies a l'absorption d'agents edulcorants | |
| JPH1129485A (ja) * | 1997-07-10 | 1999-02-02 | Kureha Chem Ind Co Ltd | 抗肥満剤 |
| JP3522708B2 (ja) * | 2001-04-11 | 2004-04-26 | 呉羽化学工業株式会社 | 経口投与用吸着剤 |
| US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| CA2504514C (en) * | 2002-11-01 | 2008-08-12 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| KR101135260B1 (ko) | 2003-10-22 | 2012-04-12 | 가부시키가이샤 쿠레하 | 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제 |
| TWI370012B (en) | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| TWI370013B (en) | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| US20070270307A1 (en) * | 2004-05-31 | 2007-11-22 | Isao Hamasaki | Adsorbent And Process For Producing The Same |
| JPWO2005117920A1 (ja) * | 2004-06-02 | 2008-04-03 | 株式会社クレハ | 循環器機能障害因子除去剤 |
| US8247072B2 (en) | 2006-02-14 | 2012-08-21 | Eastman Chemical Company | Resol beads, methods of making them and methods of using them |
| WO2008066778A2 (en) * | 2006-11-27 | 2008-06-05 | Denovo, Inc. | Decontaminant edible product, methods of production and uses thereof |
| JP5985027B2 (ja) * | 2010-10-12 | 2016-09-06 | フタムラ化学株式会社 | 経口投与用医薬用吸着剤の製造方法 |
| JP5984352B2 (ja) * | 2010-10-12 | 2016-09-06 | フタムラ化学株式会社 | 経口投与用医薬用吸着剤の製造方法 |
| CN104797243A (zh) | 2012-09-21 | 2015-07-22 | 辉凌公司 | 药物组合物 |
| EP2978413A1 (en) | 2013-03-25 | 2016-02-03 | Ferring BV | Composition for the treatment of disease |
| KR101924201B1 (ko) * | 2014-02-07 | 2018-12-03 | 대원제약주식회사 | 강도가 증가된 경구 투여형 의약용 흡착제 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5018879B2 (enExample) * | 1971-08-27 | 1975-07-02 | ||
| JPS4983690A (enExample) * | 1972-12-20 | 1974-08-12 | ||
| JPS49126591A (enExample) * | 1973-04-10 | 1974-12-04 | ||
| JPS5018879A (enExample) * | 1973-06-20 | 1975-02-27 | ||
| JPS5051996A (enExample) * | 1973-09-11 | 1975-05-09 | ||
| DE2410372C2 (de) * | 1974-03-05 | 1982-03-04 | Kureha Kagaku Kogyo K.K., Tokyo | Verfahren zum Reaktivieren von verbrauchter praktisch kugelförmiger Aktivkohle kleiner Größe |
| JPS51148291A (en) * | 1975-06-13 | 1976-12-20 | Teijin Ltd | Artificial organ |
| JPS51151693A (en) * | 1975-06-23 | 1976-12-27 | Eisai Co Ltd | Coated bead-like activated carbon for blood purification |
-
1977
- 1977-12-27 JP JP15654677A patent/JPS5489010A/ja active Granted
-
1978
- 1978-12-22 GB GB7849806A patent/GB2012257B/en not_active Expired
- 1978-12-22 DE DE2855825A patent/DE2855825C2/de not_active Expired
- 1978-12-22 CA CA318,549A patent/CA1112172A/en not_active Expired
- 1978-12-26 ES ES476321A patent/ES476321A1/es not_active Expired
- 1978-12-26 FR FR7836293A patent/FR2413092A1/fr active Granted
- 1978-12-27 NL NL7812550A patent/NL7812550A/xx active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| FR2413092A1 (fr) | 1979-07-27 |
| NL7812550A (nl) | 1979-06-29 |
| DE2855825A1 (de) | 1979-06-28 |
| JPS5489010A (en) | 1979-07-14 |
| DE2855825C2 (de) | 1984-03-01 |
| ES476321A1 (es) | 1979-06-16 |
| GB2012257B (en) | 1983-03-30 |
| GB2012257A (en) | 1979-07-25 |
| FR2413092B1 (enExample) | 1982-11-19 |
| JPS627169B2 (enExample) | 1987-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1112172A (en) | Antidote consisting of particles of activated carbon | |
| US4822765A (en) | Process for treating activated carbon with aqueous ammonia | |
| CA1139673A (en) | Spherical particles of activated carbon suitable for use as an antidotal pharmaceutical composition | |
| US4681764A (en) | Porous and spherical carbonaceous product | |
| TWI319985B (en) | Adsorbent for oral administration, agent for treating or preventing renal disease, and agent for treating or preventing liver disease | |
| CN1099288C (zh) | 用于治疗炎性肠疾病的药用组合物 | |
| JP2002308785A (ja) | 経口投与用吸着剤 | |
| KR910004018B1 (ko) | 복합 인산염 흡착제 | |
| WO2009078782A1 (en) | Method and means for producing bronchorelaxation | |
| KR970002613B1 (ko) | 항네프로제증후군제 | |
| CN1098688C (zh) | 治疗痔疾病用药用组合物 | |
| JPH05155776A (ja) | 高リン血症治療剤 | |
| JPS6360009B2 (enExample) | ||
| US5240700A (en) | Pharmaceutical composition comprising a medicament and 3-oxygermylpropionic acid | |
| JPH0422618B2 (enExample) | ||
| KR820000684B1 (ko) | 활성탄 입자로 된 해독제의 제조방법 | |
| WO2011161096A1 (en) | Iodinated activated charcoal for treating symptoms of depression | |
| KR870002160B1 (ko) | 변성 점토의 제조방법 | |
| JP2799553B2 (ja) | 抗痔疾患剤 | |
| KR840001449B1 (ko) | 다공성 구상 탄소질 생성물의 제조방법 | |
| JP4311923B2 (ja) | 経口投与用肝疾患治療又は予防剤 | |
| EP0435693B1 (en) | Pharmaceutical compositions containing 3-oxygermylpropionic acid polymers for inhibiting the degeneration of cells | |
| HK1083004B (en) | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |